Ameloblastoma is characterized by heterogeneity regarding its pathogenetic development, molecular abnormalities, and clinical course. Determining the molecular basis underlying these important differences remains challenging. Nevertheless, identifying molecules that influence tumor behavior would be the first steps towards gaining some insights into its pathobiology. MDM2, a 90-95kDa protein coded by a mdm2 gene which is mapped on chromosome 12q13-14. MDM2 is a negative regulator of p53 activity, through binding to the transcriptional activation domain of p53 leading to proteasome-mediated degradation, Cortactin, a product of CTTN gene, mapped to human chromosome 11q13 regulates actin-related (Arp2/3) complex induction of actin polymerization during invadopodia formation, thereby promoting cell motility. This has been accomplished through its involvement in all steps of the invadosome lifecycle, from the assembly, maturation, proteolytic activity, and disassembly. This study aims to evaluate the association of both MDM2 and Cortactin expression in solid ameloblastoma and its malignant counterpart and analyzing their significance. 10 cases of SAB with its different histologic variants and 20 cases malignant variants of ameloblastoma tumors were collected. An immunohistochemical investigation using, Cortactin, and MDM2 antibodies were done for all specimens. There was a statistically significant difference between malignant group and benign group. According to the current study Cortactin and MDM2 can be useful when considering the diagnosis of malignancy.
Purpose:The extent of invasion can be analyzed by the expression and production of various genes and proteins by lesional cells. However, current clinical parameters lack the potential to predict the neoplastic behavior in solid ameloblastoma (SAB) and odontogenic keratocyst (OKC). Cortactin, an F-actin binding protein, overexpression has been correlated with advanced clinic pathological stage and poor prognosis in several tumors. E-cadherin belongs to the classical cadherins which. Low E-cadherin expression correlated to aggressive, poorly differentiated, high-grade carcinomas and low patient survival. Human-murine double minute 2 (MDM2), contributes to the promotion of cell growth, survival, invasion, and therapeutic resistance, overexpression of MDM2 has been observed in various human cancers and can contribute to genomic instability, thus, further promoting tumorigenesis. The purpose of this work was to investigate the role of Cortactin, E-Cadherin, MDM2 proteins expression in SAB and OKC and correlate the expression of these markers with the aggressive behavior of these tumors. Material and method: 10 case of solid ameloblastoma with its different histologic variants and 10 cases of the keratocystic odontogenic tumor were collected as paraffin embedded blocks. An immunohistochemical investigation using, Cortactin, E-Cadherin, and MDM2 antibodieswere done for all specimens. Results: The mean area percent of immunoexpression of Cortactin was greatest in SAB while, the mean area percent of immunoexpression of E-Cadherin, MDM2 were greatest in OKC. Conculsion:According to the current study, the absence of any significant differences between AB and OKC indicate the neoplastic and aggressive nature of OKC similar to AB.
Purpose: This study aimed to evaluate the chemoprevention efficacy of diosmin on experimentally induced hamster buccal pouch (HBP) squamous cell carcinoma utilizing Ki 67 as a proliferative marker. Material and Methods: Seventy Syrian male hamsters were used as experimental animals, these hamsters were divided into five groups, Group I (negative control): 5 hamsters were left untreated. Group II (DMBA treated group): 20 hamsters were divided equally into two subgroups, painted with 0.5% DMBA where subgroup IIa: for 8 weeks while subgroup IIb: for 14 weeks. Group III: 5 hamsters were orally administrated diosmin 150 mg/kg for 14 weeks. Group IV: 20 hamsters were divided equally into two subgroups, treated with diosmin 100mg/kg and DMBA where subgroup IVa: for 8 weeks while subgroup IVb: for 14 weeks. Group V: 20 hamsters were divided equally into two subgroups, treated with diosmin 150mg/ kg and DMBA where subgroup Va: for 8 weeks while subgroup Vb: for 14 weeks.Results: Comparing all groups and subgroups revealed that the mean values have been arranged with the following descending pattern subgroup IIa, subgroup Va, subgroup IIb, subgroup Vb, subgroup IVb, subgroup IVa, group III and group I. ANOVA test revealed a statistically significant difference between groups. Conclusion: Diosmin 100mg/kg is considered a promising chemopreventive agent in preventing induced HBP squamous cell carcinoma.
Purpose:The aim of this study was to assess the presence and correlation of CD44 in selected malignant salivary glands tumors (SGTs), carcinoma ex pleomorphic (Ca ex PA), mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) histopathological variants. Material and Methods: Thirty-five formalin fixed paraffin embedded blocks of both normal and malignant salivary gland specimens were included. Immunohistochemical analysis was employed to assess the expression of CD44. Results: In the present study, comparing all groups revealed that the highest value was recorded in MEC, followed by ACC, then Ca ex PA, while the lowest mean was recorded in normal salivary tissue. ANOVA tests indicated that all groups had statistically significant differences (p=0,00). Comparing all subtypes of ACC revealed a significant difference between solid pattern and cribriform tubular patterns. Also, there is a significant difference between the high and low grades MEC. Conclusion: According to the current study, the pattern of expression of CD44 was correlated with the histopathological variants and serve as tumor behavior indicator.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.